130 results on '"Stangl‐Kremser, Judith"'
Search Results
2. Intermediate Grade Prostate Cancer and Risk for Adverse Pathology Radical Prostatectomy: Implications for Partial Gland Ablation Case Selection
3. Partial-gland Cryoablation Outcomes for Localized Prostate Cancer in Patients with Magnetic Resonance Imaging (MRI)-visible and MRI-invisible Lesions
4. Study protocol for a prospective, multi-centered randomized controlled trial comparing pelvic fascia-sparing radical prostatectomy with conventional robotic-assisted prostatectomy: The PARTIAL trial
5. Enhancing Recovery After Major Bladder Cancer Surgery: Comprehensive Review and Assessment of Application of the Enhanced Recovery After Surgery Guidelines
6. The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis
7. Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature
8. Psoas Muscle Mass can Predict Postsurgical Outcomes in Patients Who Undergo Radical Cystectomy and Urinary Diversion Reconstruction
9. Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI)
10. Impact of Patients’ Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis
11. PD01-11 PHASE I DOSE-ESCALATION TRIAL OF MULTIPLE AND FRACTIONATED-DOSE PSMA-TARGETED ALPHA RADIONUCLIDE (225AC-J591) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
12. ASSESSMENT OF PSMA PET IMAGING RESPONSE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER 225AC-J591 THERAPY: POST-HOC PATIENT-LEVEL ANALYSIS OF A PROSPECTIVE CLINICAL TRIAL
13. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia
14. Association of Hyponatremia With Survival in Patients With Castration-resistant Prostate Cancer: A Clinical Commentary
15. Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer
16. Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder
17. Application of the ERAS guidelines in pediatric urological surgery: a systematic review.
18. Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: A systematic review and meta-analysis
19. Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype
20. Role of HIFU in Cancer Management
21. Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591.
22. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients
23. α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States.
24. Integrative multi-region molecular profiling of primary prostate cancer with synchronous lymph node metastasis to characterize the biologically dominant clone
25. Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer
26. Response to RL‐225Ac in prostate cancer: Effect of prior treatment with RL‐177Lu: A systematic review of the literature
27. Intermediate Grade Prostate Cancer and Risk for Adverse Pathology at Radical Prostatectomy: Implications for Partial Gland Ablation Case Selection
28. MP29-10 PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED RADIONUCLIDE THERAPY (TRT)
29. Transperineal vs. transrectal biopsy to reduce postinterventional sepsis
30. Partial gland ablation outcomes for localized prostate cancer in patients with MRI-visible and MRI-invisible lesions.
31. Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.
32. Prognostic value of neutrophil‐to‐lymphocyte ratio in patients with metastatic castration‐resistant prostate cancer receiving prostate‐specific membrane antigen targeted radionuclide therapy.
33. MP47-04 VALIDATION OF A 22-GENE EPITHELIAL-MESENCHYMAL TRANSITION (EMT) PROGNOSTIC SIGNATURE IN CLEAR CELL RENAL CELL CARCINOMA
34. Validation of a 22-gene epithelial-mesenchymal transition (EMT) prognostic signature in clear cell renal cell carcinoma.
35. Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
36. PD40-01 CHARACTERIZATION OF THE TUMOR IMMUNE MICROENVIRONMENT IN CLEAR CELL RENAL CELL CARCINOMA (ccRCC): PROGNOSTIC VALUE AND THERAPEUTIC IMPLICATIONS OF AN M0-MACROPHAGE ENRICHED SUBTYPE
37. Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis
38. Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer
39. Single-lesion PSMA protein expression and response to Lu-177 PSMA therapy in patients with castration-resistant prostate cancer.
40. Characterization of the tumor immune microenvironment in clear cell renal cell carcinoma (ccRCC): Prognostic value and therapeutic implications of an M0-macrophage enriched subtype.
41. Thyroid and androgen receptor signaling are antagonized by μ‐Crystallin in prostate cancer
42. Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI)
43. The prognostic impact of tumour NSD2 expression in advanced prostate cancer
44. Therapeutic management of Bacillus Calmette–Guerin refractory patients: a narrative review
45. Vergleich der Radiotherapie mit radikaler Zystektomie in Patienten, die für eine systematische Chemotherapie nicht geeignet sind
46. Risikofaktoren für eine Harnwegsinfektion bei Männern, die eine TURP bei subvesikaler Obstruktion erhalten
47. Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer
48. Radikale Zystektomie vs. Radiotherapie in alte und morbide Patienten mit resektablem Blasenkarzinom
49. Sarkopenie als prognostischer Marker bei Patienten mit radiotherapeutischer Behandlung des Blasenkarzinoms
50. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.